Clinuvel to showcase SCENESSE® drug for treating vitiligo at AAD Annual Meeting.

From GlobeNewswire: 2025-03-03 21:17:55

CLINUVEL, a leading photomedicine company, will debut at the American Academy of Dermatology Annual Meeting with an immersive exhibition showcasing the history, evolution, and future of photomedicine. The Pavilion of Photomedicine will highlight CLINUVEL’s development program with the novel drug SCENESSE® to treat vitiligo. Visitors will experience curated courts, a 360° video installation, and a “Derma Hall of Fame” honoring pioneers in the field. The exhibit aims to increase understanding and empathy for vitiligo, a condition that affects millions worldwide. CLINUVEL’s FDA-approved melanocortin technology has shown promise in treating vitiligo and other disorders.

The AAD Annual Meeting, the largest gathering of dermatologists, researchers, and industry professionals, will feature CLINUVEL’s Pavilion of Photomedicine, open to delegates from March 7-9 at Booth 881. The company’s senior and global clinical teams will be available to discuss current and future programs. Journalists at AAD 2025 can book a visit to the Pavilion and arrange interviews. CLINUVEL is trialling the first systemic therapy in vitiligo to offer extensive repigmentation without suppressing the immune system.

CLINUVEL is a global specialty pharmaceutical group focused on developing treatments for genetic, metabolic, and life-threatening disorders. Their lead therapy, SCENESSE®, is the world’s first systemic photoprotective drug for patients with erythropoietic protoporphyria. Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Singapore, and the USA. For more information, visit www.clinuvel.com/aad-annual-meeting-2025.



Read more at GlobeNewswire: Clinuvel Introduces Groundbreaking Vitiligo Program at the